Optomyelitis associated with the presence of antibodies to myelin oligodendrocyte glycoprotein. Case report

Cover Page

Cite item

Full Text

Abstract

Antibodies to myelin-oligodendrocyte glycoprotein (anti-MOG-IgG) is a specific biomarker that has been detected in peripheral blood from children with acute multiple encephalomyelitis (ADEM) as well as in adults with aquaporin-4 (AQP4), associated with seronegative opticoneuromyelitis spectrum disease (NMOSD), brainstem encephalitis, longitudinally disseminated transverse myelitis, and optic neuritis. Most experts now consider MOG-IgG-associated disorder (MOG-AD) an independent disease immunopathogenetically distinct from classical multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive optomyelitis. Isolated, bilateral, and less frequently unilateral OH, with simultaneous or sequential involvement of the eyes, is the most frequent clinical manifestation of MOG-AD. Because of the significant overlap in the clinical and radiological picture, MOG-AD is often misdiagnosed as MS. Timely diagnosis is critical to ensure appropriate treatment. This article describes a clinical case of anti-MOG-IgG encephalomyelitis with late-onset ON initially diagnosed as MS.

About the authors

Anastasiia K. Kalashnikova

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: kalashnic94@yandex.ru
ORCID iD: 0000-0002-2229-384X

Graduate Student, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Nataliia L. Sheremet

Research Institute of Eye Diseases

Email: kalashnic94@yandex.ru
ORCID iD: 0000-0003-4597-4987

D. Sci. (Med.), Research Institute of Eye Diseases

Russian Federation, Moscow

Natalia A. Andreeva

Research Institute of Eye Diseases

Email: kalashnic94@yandex.ru
ORCID iD: 0000-0001-7329-5725

Cand. Sci. (Med.), Research Institute of Eye Diseases

Russian Federation, Moscow

Nino V. Zhorzholadze

Research Institute of Eye Diseases

Email: kalashnic94@yandex.ru
ORCID iD: 0000-0003-1771-300X

Cand. Sci. (Med.), Research Institute of Eye Diseases

Russian Federation, Moscow

Irina A. Ronzina

Research Institute of Eye Diseases

Email: kalashnic94@yandex.ru
ORCID iD: 0000-0002-0298-2250

Cand. Sci. (Med.), Research Institute of Eye Diseases

Russian Federation, Moscow

Anna A. Kaloshina

Research Institute of Eye Diseases

Email: kalashnic94@yandex.ru
ORCID iD: 0000-0002-4385-2866

Graduate Student, Research Institute of Eye Diseases

Russian Federation, Moscow

References

  1. Voss E, Raab P, Trebst C, Stangel M. Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. Ther Adv Neurol Disord. 2011;4(2):123-34. doi: 10.1177/1756285611398702
  2. Petzold A, Plant GT. Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev. 2014;13(4-5):539-45. doi: 10.1016/j.autrev.2014.01.009
  3. Weerasinghe D, Lueck C. Mimics and chameleons of optic neuritis. Pract Neurol. 2016;16(2):96-110. doi: 10.1136/practneurol-2015-001254
  4. Chen JJ, Pittock SJ, Flanagan EP, et al. Optic neuritis in the era of biomarkers. Surv Ophthalmol. 2020;65(1):12-7. doi: 10.1016/j.survophthal.2019.08.001
  5. Di Pauli F, Berger T. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? Front Immunol. 2018;9:2753. doi: 10.3389/fimmu.2018.02753
  6. Nakajima H, Motomura M, Tanaka K, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5(4):e007766. doi: 10.1136/bmjopen-2015-007766
  7. Sepúlveda M, Armangue T, Martinez-Hernandez E, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016;263(7):1349-60. doi: 10.1007/s00415-016-8147-7
  8. Akaishi T, Sato DK, Takahashi T, Nakashima I. Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. Neurochem Int. 2019;130:104319. doi: 10.1016/j.neuint.2018.10.016
  9. Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134. doi: 10.1186/s12974-018-1144-2
  10. Елисеева Д.Д., Васильев А.В., Шабалина А.А., и др. Энцефаломиелиты, ассоциированные с антителами к миелинолигодендроцитарному гликопротеину. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(7-2):13-23 [Eliseeva DD, Vasiliev AV, Shabalina AA, et al. Myelin oligodendrocyte glycoprotein immunoglobulin G-associated encephalomyelitis. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(7-2):13-23 (in Russian)]. doi: 10.17116/jnevro202012007213
  11. Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128-38. doi: 10.1093/brain/awx276
  12. Щепарева М.Е., Кочергин И.А., Толпеева О.А., и др. Диагностическое значение антител к миелин-олигодендроцитарному гликопротеину при демиелинизирующих заболеваниях центральной нервной системы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(2-2):18-23 [Shchepareva ME, Kochergin IA, Tolpeeva OA, et al. Diagnostic value of antibodies to myelin oligodendrocyte glycoprotein in demyelinating diseases of the central nervous system. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(2-2):18-23 (in Russian)].
  13. Zheng Y, Cai MT, Li EC, et al. Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Masquerading as Multiple Sclerosis: An Under-Recognized Entity? Front Immunol. 2021;12:671425. doi: 10.3389/fimmu.2021.671425
  14. Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346-51. doi: 10.1136/jnnp-2017-316286
  15. Juryńczyk M, Tackley G, Kong Y, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2017;88(2):132-6. doi: 10.1136/jnnp-2016-314005
  16. Dubey D, Pittock SJ, Krecke KN, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019;76(3):301. doi: 10.1001/jamaneurol.2018.4053
  17. Ciron J, Cobo-Calvo A, Audoin B, et al. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Mult Scler. 2020;26(8):936-44. doi: 10.1177/1352458519849511
  18. Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127-37. doi: 10.1136/jnnp-2017-316880
  19. Fang W, Zheng Y, Yang F, et al. Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2020;13:175628641989859. doi: 10.1177/1756286419898594
  20. Jarius S, Ruprecht K, Kleiter I, et al. Mog-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 1: Frequency, Syndrome Specificity, Influence of Disease Activity, Long-Term Course, Association With AQP4-IgG, and Origin. J Neuroinflammation. 2016;13(1):279. doi: 10.1186/s12974-016-0717-1
  21. Brayo P, Shah S. MOG-IgG Associated Disease (MOG-AD) in Adults. Curr Treat Options Neurol. 2021;23(6):17. doi: 10.1007/s11940-021-00672-6
  22. Narayan RN, McCreary M, Conger D, et al. Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients. Mult Scler Relat Disord. 2019;28:86-90. doi: 10.1016/j.msard.2018.11.026
  23. Outteryck O, Majed B, Defoort-Dhellemmes S, et al. A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler. 2015;21(14):1781-93. doi: 10.1177/1352458515578888
  24. Havla J, Pakeerathan T, Schwake C, et al. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation. 2021;18(1):121. doi: 10.1186/s12974-021-02160-9
  25. Filippatou AG, Mukharesh L, Saidha S, et al. AQP4-IgG and MOG-IgG Related Optic Neuritis–Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:540156. doi: 10.3389/fneur.2020.540156
  26. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. doi: 10.1186/s12974-016-0718-0
  27. Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572. doi: 10.1212/NXI.0000000000000572
  28. Peschl P, Bradl M, Höftberger R, et al. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Front Immunol. 2017;8:529. doi: 10.3389/fimmu.2017.00529
  29. Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018;195:8-15. doi: 10.1016/j.ajo.2018.07.020
  30. Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1100. doi: 10.1212/NXI.0000000000001100

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies